Clinuvel Pharmaceuticals Limited (CUV:ASX)

$41.71

right-arrow Created with Sketch. 0.61 (1.48%)
MCAP $2.030B
Last trade 16.10pm 17/09/2021 20mins delayed

Latest Announcements

16/09/2021CUVClinuvel Pharmaceuticals Limited
14/09/2021CUVClinuvel Pharmaceuticals Limited
27/08/2021CUVClinuvel Pharmaceuticals Limited
26/08/2021CUVClinuvel Pharmaceuticals Limited
26/08/2021CUVClinuvel Pharmaceuticals Limited
26/08/2021CUVClinuvel Pharmaceuticals Limited
26/08/2021 Price SensitivePSCUVClinuvel Pharmaceuticals Limited
26/08/2021 Price SensitivePSCUVClinuvel Pharmaceuticals Limited

Company Overview

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.

CUV in the news

Clinuvel Pharmaceuticals (CUV) is expanding its clinical programme to test Scensse’s ability…
Clinuvel Pharmaceutical’s (CUV) marked its decade of consecutive half-year profits with a…
Skincare specialist Clinuvel Pharmaceuticals (CUV) has been growing customer receipts and cash…
Clinuvel Pharmaceuticals (CUV) has received approved registration from the Therapeutic Goods Administration…

Search Previous Announcements